Moderna Vaccine More Effective Than Pfizer, J&J, Especially After 4 Months: CDC
- ByCNBC-
Moderna's vaccine is slightly more effective than Pfizer's or J&'s in preventing hospitalization, though the gap widens substantially after four months.
Moderna's vaccine is slightly more effective than Pfizer's or J&'s in preventing hospitalization, though the gap widens substantially after four months.
The Janssen Pharmaceutical of Johnson & Johnson (JNJ) has disclosed results from a Phase 1b/2 study designed to evaluate BALVERSA (erdafitinib) plus cetrelimab versus BALVERSA...
Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (NYSE: JNJ) Ebola vaccine regimen showed a long-lasting immune...
Leading pharmaceutical giant, Johnson & Johnson, is breaking below its important 200-day moving average today. The stock has been steadily declining since August 20th, 2021.
Investors seeking the safety and security of a stream of dividend income from a ‘AAA’ rated stock might want to consider investing in JNJ.
"The global health industry was worth $8.45 trillion in 2018 and global healthcare could reach over $10 trillion by 2022," according to PolicyAdvice a US insurance specialist. And...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Buy | Sell | Strong Sell | Buy |
| Technical Indicators | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 19.17 | 19.57 | 18.99 | +0.06 | +0.31% | 239.68K | Toronto | |||
| 9.71 | 9.88 | 9.61 | -0.17 | -1.72% | 2.30M | Toronto | |||
| 20.93 | 21.54 | 20.84 | -0.39 | -1.83% | 451.33K | Toronto | |||
| 0.75 | 0.00 | 0.00 | +0.1000 | +15.38% | 143.61K | TSXV | |||
| 18.72 | 19.01 | 18.55 | -0.090 | -0.48% | 2.09M | Toronto | |||
| 13.33 | 13.38 | 13.04 | 0.00 | 0.00% | 636.21K | Toronto | |||
| 43.60 | 43.64 | 42.75 | +0.53 | +1.23% | 335.82K | Toronto | |||
| 4.89 | 4.90 | 4.89 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 0.175 | 0.00 | 0.00 | +0.030 | +20.69% | 2.00K | Toronto | |||
| 8.45 | 8.46 | 8.20 | +0.050 | +0.60% | 790.64K | Toronto | |||
| 99.31 | 99.70 | 97.79 | +0.79 | +0.80% | 1.24M | Toronto | |||
| 23.02 | 23.23 | 22.62 | -0.08 | -0.35% | 2.56M | Toronto | |||
| 15.56 | 15.65 | 15.47 | -0.09 | -0.58% | 2.00K | Toronto | |||
| 52.54 | 52.64 | 51.82 | -0.130 | -0.25% | 2.45M | Toronto | |||
| 0.06 | 0.00 | 0.00 | 0.000 | 0.00% | 115.00K | TSXV |
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.